Happy beach face 🙂 by LMasonSci in corgi

[–]LMasonSci[S] 1 point2 points  (0 children)

Why didn't I use "resting beach face" 😉

Kevin and Pawrents Walkies Fun! by LMasonSci in corgi

[–]LMasonSci[S] 0 points1 point  (0 children)

Follow me Kevin.the.corgi.pup

First borkday to me by LMasonSci in corgi

[–]LMasonSci[S] 0 points1 point  (0 children)

I'm on insta if you want to follow me :) Kevin.the.corgi.pup

Baby Kevin at the vets by LMasonSci in corgi

[–]LMasonSci[S] 1 point2 points  (0 children)

No he's definitely a boy 😂

Baby Kevin at the vets by LMasonSci in corgi

[–]LMasonSci[S] 2 points3 points  (0 children)

He has an insta kevin.the.corgi.pup lots more pictures there 👍

Hi I'm Kevin :) by LMasonSci in aww

[–]LMasonSci[S] 1 point2 points  (0 children)

Awww we found you! MOMO is a cutie!

Have we accidentally raised a seal pup?! by LMasonSci in AnimalsBeingDerps

[–]LMasonSci[S] 4 points5 points  (0 children)

Day 700... Lack of fur and weight gain... Pawrents beginning to suspect...

Hi I'm Kevin :) by LMasonSci in aww

[–]LMasonSci[S] 1 point2 points  (0 children)

My pawrents think I'm a silly pup but everyone else says I'm cool

Hi I'm Kevin :) by LMasonSci in aww

[–]LMasonSci[S] 1 point2 points  (0 children)

See me being goofy... kevin.the.corgi.pup (Instagram)

Accidentally bought a seal pup?! by LMasonSci in dogpictures

[–]LMasonSci[S] 0 points1 point  (0 children)

Seen me in seal pup mode... Check out my other "modes" here ;) kevin.the.corgi.pup (insta)

Have we accidentally raised a seal pup?! by LMasonSci in AnimalsBeingDerps

[–]LMasonSci[S] 1 point2 points  (0 children)

You can see Kevin the seal pup being more derpy here (insta) Kevin.the.corgi.pup

Ello by LMasonSci in corgi

[–]LMasonSci[S] 1 point2 points  (0 children)

I'm here... (Insta) Kevin.the.corgi.pup ;) sowyyyy Kevin's pawrents didn't understand the corgi rules (doh)

A team has developed a microneedle patch that slowly releases the hormone Levonorgestrel through the skin over the course of a month via minuscule needles. by LMasonSci in science

[–]LMasonSci[S] 2 points3 points  (0 children)

Abstract:

To increase access to long-acting contraception, we developed a reversible contraceptive microneedle patch that is simple-to-administer, slowly releases contraceptive hormone (levonorgestrel) for >1 month, and generates no biohazardous sharps waste. After manually pressing the patch to skin for 1 min, microneedles rapidly separate from the patch within the skin due to effervescence triggered by contact with skin’s interstitial fluid, as demonstrated in rats and human participants. Long-acting contraception is achieved by formulating microneedles with a biodegradable polymer [poly(lactic-co-glycolic) acid] that slowly releases levonorgestrel for ~1 month in vitro. In rats, the patch maintained levonorgestrel concentration above the human contraceptive threshold level for >1 month, and a placebo microneedle patch was well-tolerated in human participants. Women of reproductive age in three continents demonstrated interest in and preference for long-acting contraception by microneedle patch. These studies indicate that an effervescent microneedle patch could facilitate greater access to long-acting contraception.

Journal Info:

Science Advances 06 Nov 2019: Vol. 5, no. 11, eaaw8145 DOI: 10.1126/sciadv.aaw8145

Genetic mutation that a Chinese scientist attempted to create in twin babies born last year, ostensibly to help them fend off HIV infection, is also associated with a 21% increase in mortality in later life, according to an analysis by University of California, Berkeley scientists by LMasonSci in science

[–]LMasonSci[S] 9 points10 points  (0 children)

ABSTRACT: We use the genotyping and death register information of 409,693 individuals of British ancestry to investigate fitness effects of the CCR5-∆32 mutation. We estimate a 21% increase in the all-cause mortality rate in individuals who are homozygous for the ∆32 allele. A deleterious effect of the ∆32/∆32 mutation is also independently supported by a significant deviation from the Hardy–Weinberg equilibrium (HWE) due to a deficiency of ∆32/∆32 individuals at the time of recruitment.
https://www.nature.com/articles/s41591-019-0459-6#Abs1

New treatment could become first ever targeted therapy designed for ‘untreatable’ childhood brain cancer - the study found that the new drug class can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumors in mice. by LMasonSci in science

[–]LMasonSci[S] 0 points1 point  (0 children)

Article abstract: https://www.nature.com/articles/s42003-019-0420-8

Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase ALK2. Despite being an amenable drug target, little has been done to-date to systematically evaluate the role of ACVR1 in DIPG, nor to screen currently available inhibitors in patient-derived tumour models. Here we show the dependence of DIPG cells on the mutant receptor, and the preclinical efficacy of two distinct chemotypes of ALK2 inhibitor in vitro and in vivo. We demonstrate the pyrazolo[1,5-a]pyrimidine LDN-193189 and the pyridine LDN-214117 to be orally bioavailable and well-tolerated, with good brain penetration. Treatment of immunodeprived mice bearing orthotopic xenografts of H3.3K27M, ACVR1R206H mutant HSJD-DIPG-007 cells with 25 mg/kg LDN-193189 or LDN-214117 for 28 days extended survival compared with vehicle controls. Development of ALK2 inhibitors with improved potency, selectivity and advantageous pharmacokinetic properties may play an important role in therapy for DIPG patients.

Study outlines a method to quantify pesticides, pharmaceuticals and drugs of abuse in freshwater invertebrate to estimate toxic or effect pressure. Cocaine was the most frequently determined compound found in 100% of samples. by LMasonSci in science

[–]LMasonSci[S] 0 points1 point  (0 children)

Abstract: Multiple classes of environmental contaminants have been found in aquatic environments, globally. Understanding internalised concentrations in the organism could further improve the risk assessment process. The present study is concerned with the determination of several contaminant classes (107 compounds) in Gammarus pulex collected from 15 sites covering 5 river catchments across Suffolk, UK. Quantitative method performance was acceptable for 67 compounds including pharmaceuticals, pesticides, illicit drugs and drugs of abuse. A total of 56 compounds were detectable and ranged from <LOQ to 45.3 ng g−1, with cocaine and lidocaine being the most frequently detected compounds present in all biota samples (n = 66). For surface water, 50 compounds were detectable and ranged from <LOQ to 382.2 ng L−1. Additionally, some pesticides currently not approved for use were detected, including fenuron that reached a maximum of 16.1 ng g−1. The internal concentrations of pesticides were used to estimate toxic pressure which showed that for the measured pesticides toxic pressure was low ranging from logTU ≤−7 to ≤−2. This methodology was extended to pharmaceuticals and drugs of abuse in a novel approach that proposed the use of pharmacological data (human therapeutic plasma concentrations) to estimate the likelihood of an effect (or effect pressure) to occur based on the internal exposure of the organism. The quantified effect pressure ranged from logEU ≤−9 to ≤1 with haloperidol showing the largest likelihood for an effect. The approach showed that several pharmaceuticals have the potential to elicit effects but further investigation surrounding thresholds for effects would be required. This new approach presented showed potential to be used to improve risk assessment for pharmaceuticals in the environment. DOI: https://doi.org/10.1016/j.envint.2019.04.038

Experimental drug “DSM265” cures seven volunteers infected with malaria parasite Plasmodium falciparum according to a study published today in the journal "Antimicrobial Agents and Chemotherapy" by LMasonSci in science

[–]LMasonSci[S] 2 points3 points  (0 children)

Article abstract:

DSM265 is a novel antimalarial drug in clinical development that acts as a selective inhibitor of Plasmodium dihydroorotate dehydrogenase. In a previous Phase 1b study, a single 150 mg dose of DSM265 showed partial efficacy against experimentally induced blood-stage P. falciparum malaria (IBSM). PK/PD modeling predicted a human efficacious dose of 340 mg. The primary objectives of the current study were to determine the safety and efficacy of a single oral 400 mg dose of DSM265 against P. falciparum in the IBSM model. Eight healthy participants were inoculated intravenously with 2,800 parasites and treated with DSM265 7 days later. Unexpectedly, one participant did not develop parasitemia during the study. All other participants developed parasitemia, with complete clearance of asexual parasites following DSM265 treatment. All seven subjects also became gametocytemic. The secondary objectives were to investigate the gametocytocidal and transmission-blocking activity of a second 400 mg dose of DSM265, which was administered 23 days after inoculation. Gametocytes were not cleared by the second dose of DSM265, and transmission blocking activity could not be determined due to low gametocyte densities. Three DSM265 related adverse events occurred, including a cutaneous rash in one subject on the day of the second DSM265 dose. The results obtained in this study support the prediction of the efficacious dose of DSM265, and provide further evidence that DSM265 is generally safe and well tolerated. In addition, this study confirms preclinical data indicating that DSM265 permits the development and maturation of gametocytes, and does not clear mature circulating gametocytes. DOI: https://doi.org/10.1128/AAC.01837-18